Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cladribine - Johnson and Johnson/Merck Serono

X
Drug Profile

Cladribine - Johnson and Johnson/Merck Serono

Alternative Names: 2-CdA; 2-Chloro-2-deoxyadenosine; 2-Chlorodeoxyadenosine; 2CDA; Chlorodeoxyadenosine; Intocel; Leustat; Leustatin; Mavenclad; Movectro; Mylinax; PRMavenclad; RWJ-26251

Latest Information Update: 21 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scripps Clinic
  • Developer EMD Serono; Janssen-Cilag; Merck Serono; Orphan Australia
  • Class Antineoplastics; Antipsoriatics; Deoxyadenosines; Purine nucleosides; Ribonucleosides; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leukaemia; Lymphoma; Hairy cell leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Hairy cell leukaemia; Leukaemia; Lymphoma; Multiple sclerosis
  • No development reported Psoriasis; Transplant rejection

Most Recent Events

  • 18 Jun 2024 Merck Healthcare KGaA plans to initiate a phase III trial for Myasthenia Gravis in the US and Germany (PO) (NCT06463587)
  • 19 Apr 2024 University of Washington in collaboration with AbbVie suspends phase I trial in phase I trial for acute myeloid leukaemia (Combination therapy, Second-line or greater therapy) in USA (IV) due to phase transition/study design changes (NCT04797767)
  • 23 May 2023 University of Washington in collaboration with AbbVie suspends phase I trial in phase I trial for acute myeloid leukaemia (Combination therapy, Second-line or greater therapy) in USA due to pending protocol amendment (IV) (NCT04797767)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top